DiaMedica Therapeutics Inc.

Listed Company

DMACCIK 0001401040NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsZ4CAFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-32.80M

Total Assets

$61.37M

Equity

$56.10M

Shares Out

53.88M

Op. Cash Flow

$-29.10M

DMAC$7.32+87.21% · past yearDBEQ Basic

Daily closing prices

Business

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing recombinant protein therapeutics for severe ischemic diseases. Its lead candidate DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, is in Phase 2 trials for preeclampsia & fetal growth restriction and Phase 2/3 trials for acute ischemic stroke, with a therapeutic window extending to 24 hours post-symptom onset. The company is developing DM300, a recombinant serine protease inhibitor, for acute pancreatitis. DiaMedica outsources manufacturing to Catalent.

Summary from 10-K filed 2026-03-30

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	25	19	13	8	9
General and administrative	10	8	8	6	5
Total operating expenses	34	27	21	14	14
Operating loss	−34	−27	−21	−14	−14
Other income, net	2	2	2	353,000	82,000
Total other income, net	2	2	2	353,000	82,000
Loss before income tax expense	−33	−24	−19	−14	−14
Income tax expense	−28,000	−30,000	−43,000	−28,000	−28,000
Net loss	−33	−24	−19	−14	−14
Unrealized gain on marketable securities	27,000	17,000	80,000	−23,000	−49,000
Comprehensive loss	−33	−24	−19	−14	−14
Basic and diluted net loss per share (in dollars per share)	−0.7	−0.6	−0.6	−0.52	−0.65
Weighted average shares outstanding basic and diluted (in shares)	47	40	33	26	21

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	16	3	5	5	5
Marketable securities	44	41	48	29	40
Prepaid expenses and other assets	481,000	227,000	411,000	251,000	197,000
Amounts receivable	258,000	236,000	369,000	82,000	130,000
Total current assets	61	45	54	34	45
Deferred offering costs	400,000	0	—	—	—
Operating lease right-of-use asset	197,000	279,000	354,000	424,000	42,000
Property and equipment, net	145,000	148,000	131,000	136,000	70,000
Deposits	0	1	0	—	—
Total non-current assets	742,000	2	485,000	560,000	112,000
Total assets	61	46	54	34	46
Accounts payable	1	940,000	926,000	734,000	509,000
Accrued liabilities	4	4	2	1	966,000
Operating lease obligation	101,000	90,000	80,000	63,000	4,000
Finance lease obligation	11,000	13,000	3,000	6,000	45,000
Total current liabilities	5	5	3	2	2
Operating lease obligation, non-current	124,000	225,000	316,000	396,000	3,000
Finance lease obligation, non-current	4,000	12,000	1,000	4,000	0
Total non-current liabilities	128,000	237,000	317,000	400,000	3,000
Commitments and Contingencies	—	—	—	—	—
Common shares, no par value; unlimited authorized; 53,742,370 and 42,818,660 shares issued and outstanding, as of December 31, 2025 and 2024, respectively	0	0	0	0	0
Paid-in capital	229	181	167	128	127
Accumulated other comprehensive income	50,000	23,000	6,000	−74,000	−51,000
Accumulated deficit	−173	−140	−116	−96	−83
Total shareholders equity	56	41	51	32	44
Total liabilities and shareholders equity	61	46	54	34	46

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation	4	2	2	2	2
Amortization of discounts on marketable securities	−942,000	−1	−1	−11,000	161,000
Non-cash lease expense	82,000	75,000	70,000	64,000	58,000
Depreciation	43,000	39,000	30,000	25,000	24,000
Prepaid expenses and other assets	−254,000	184,000	−160,000	−54,000	−123,000
Amounts receivable	−22,000	133,000	−287,000	48,000	210,000
Deposits	1	−1	0	—	−103,000
Accounts payable	535,000	14,000	192,000	225,000	−590,000
Accrued liabilities	−892,000	2	348,000	366,000	42,000
Net cash used in operating activities	−29	−22	−19	−12	−12
Purchase of marketable securities	−59	−50	−69	−46	−70
Maturities and sales of marketable securities	57	59	51	57	49
Purchase of property and equipment	−40,000	−25,000	−24,000	−81,000	−22,000
Net cash provided by (used in) investing activities	−2	9	−18	12	−21
Proceeds from the sale of common shares, net of offering costs	43	12	37	0	30
Proceed from the exercise of common stock options	1	256,000	0	0	244,000
Principal payments on finance lease obligations	−10,000	−9,000	−6,000	−6,000	−6,000
Deferred financing costs, net	−400,000	0	—	—	—
Net cash provided by financing activities	44	12	37	−6,000	30
Net increase (decrease) in cash and cash equivalents	13	−2	−185,000	21,000	−3
Cash paid for income taxes	28,000	26,000	33,000	27,000	28,000
Assets acquired under financing lease	0	30,000	0	446,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is DiaMedica Therapeutics Inc.'s CIK number?

DiaMedica Therapeutics Inc.'s SEC CIK number is 0001401040 (1401040). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find DiaMedica Therapeutics Inc.'s SEC filings?

All of DiaMedica Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did DiaMedica Therapeutics Inc. last report earnings?

DiaMedica Therapeutics Inc. (DMAC) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-015218). This is DiaMedica Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is DiaMedica Therapeutics Inc.'s most recent earnings 8-K?

DiaMedica Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001437749-26-015218. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View DiaMedica Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →